Kaitlyn D’Onofrio

DocwireNews

Adults taking <a href="https://www.docwirenews.com/abstracts/orthopedic-abstracts/lower-socioeconomic-status-is-associated-with-worse-preoperative-function-pain-and-increased-opioid-use-in-patients-with-primary-glenohumeral-osteoarthritis/">opioids</a> to control <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/trastuzumab-deruxtecan-vs-herceptin-how-do-these-breast-cancer-drugs-compare/">cancer-related pain</a> did not find any additional benefit by adding <a href="https://www.docwirenews.com/docwire-pick/cannabis-treatment-fibromyalgia/">cannabinoids</a> to their routine when compared to placebo, new research has found.Cancer-related pain affects about three in five <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/predicting-short-term-mortality-in-cancer-patients/">cancer</a> patients undergoing anti-cancer therapy and nine in 10 patients with advanced disease, according to the authors of this study. Previous research has found that cannabinoid use occurs in cancer patients, primarily to treat pain.&ldquo;The primary outcome in this systematic review was the absolute change in mean pain intensity, which is a more sensitive outcome than a dichotomous outcome, for example, proportion of participants who report a pain relief of 50% or greater from baseline to end of study. The aim was to determine the beneficial and adverse effects of cannabinoids compared with placebo or other active agents for the treatment of cancer-related pain in adults from RCTs [randomized controlled trials],&rdquo; established the researchers, whose findings were published in <a href="https://spcare.bmj.com/content/early/2020/01/08/bmjspcare-2019-002032">BMJ Supportive &amp; Palliative Care</a>.A search was performed using the following electronic databases: Embase (Ovid), Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations, PsycINFO (Ovid), Conference Proceedings Citation Index&ndash;Science (Web Of Science; Thomson Reuters, New York City, NY), ClinicalTrials.gov (US NIH), ISRCTN registry (BMC), Cochrane Database of Systematic Reviews (Wiley), Cochrane Central Register of Controlled Trials (Wiley), and Database of Abstracts of Reviews of Effect (Wiley).Eligible studies were RCTs that compared the effect of cannabinoids (THC:CBD, THC extract, nabiximols, Sativex, and medical cannabis) against placebo or other active agents to treat cancer-related pain in adult patients. The primary outcome of these studies was pain.Exclusion criteria were studies that included patients undergoing surgery, healthy volunteers, or animals; were not RCTs; and did not have pain as the primary outcome.The search yielded 2,805 studies; the systematic review included six RCTs encompassing 1,460 patients, and the meta-analysis included five studies encompassing 1,460 patients. All included RCTs had a low bias risk. The average Numeric Rating Scale pain scores did not largely differ between patients taking cannabinoids versus placebo (mean difference, &ndash;0.21; 95% confidence interval [CI], &ndash;0.48 to 0.07; P=0.14). This finding persisted even when only assessing phase III studies in the meta-analysis (mean difference, &ndash;0.02; 95% CI, &ndash;0.21 to 0.16; P=0.80). Cannabinoids were associated with a greater risk of adverse events than placebo: somnolence (odds ratio [OR]=2.69; 95% CI, 1.54&ndash;4.71; P&lt;0.001) and dizziness (OR=1.58; 95% CI, 0.99&ndash;2.51; P=0.05).The authors summarized: &ldquo;For a medication to be useful, there needs to be a net overall benefit, with the positive effects (analgesia) outweighing adverse effects. None of the included phase III studies show benefit of cannabinoids. One of the phase II studies showed benefit in their primary outcome; the other was negative in its primary outcome, although a secondary outcome was positive. When statistically pooled, there was no decrease in pain score from cannabinoids. There are, however, significant adverse effects and dropouts reported from cannabinoids. Based on evidence with a low risk of bias, cannabinoids cannot be recommended for the treatment of cancer-related pain.&rdquo;

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Latest News

Adding Cannabinoids to Opioid Regimen Does Not Improve Cancer-related Pain in Adults, According to Study

Oncology

Adults taking opioids to control cancer-related pain did not find any additional benefit by adding cannabinoids to their routine when compared to placebo, new research has ...

Adding Cannabinoids to Opioid Regimen Does Not Improve Cancer-related Pain in Adults, According to

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe